315 related articles for article (PubMed ID: 18630457)
1. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
[TBL] [Abstract][Full Text] [Related]
2. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
Boccia R; Lillie T; Tomita D; Balducci L
Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
[TBL] [Abstract][Full Text] [Related]
4. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.
Eisterer W; Hussl C; Erb H; Haslbauer F; Sormann S; Braun S; Jaeger C
Curr Med Res Opin; 2011 Feb; 27(2):355-63. PubMed ID: 21166611
[TBL] [Abstract][Full Text] [Related]
5. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D
Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
9. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
Beer TM; Bergenstock M; Birt K; Higano CS
Clin Genitourin Cancer; 2007 Jun; 5(5):329-33. PubMed ID: 17645830
[TBL] [Abstract][Full Text] [Related]
11. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
[TBL] [Abstract][Full Text] [Related]
12. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
13. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
Ichinose Y; Seto T; Nishiwaki Y; Ohe Y; Yamada Y; Takeda K; Saijo N; Hotta T
Jpn J Clin Oncol; 2010 Jun; 40(6):521-9. PubMed ID: 20508073
[TBL] [Abstract][Full Text] [Related]
15. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
18. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
19. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
[TBL] [Abstract][Full Text] [Related]
20. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
